In ultra-fast FDA nod, Bristol Myers’ Opdivo catapults I-O to presurgery lung cancer with a first glimpse of key data
When lots of regulatory priorities are given to COVID-19 products during the pandemic, the FDA has doled out an ultra-fast cancer approval within the same week of accepting an application, introduc | When lots of regulatory priorities are given to COVI…
